BACKGROUND NOTE: Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from the published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where the available empirical data accurately reflect immunization system performance and those where the data are likely to be compromised and present a misleading view of immunization coverage while jointly estimating the most likely coverage levels for each country.

WHO and UNICEF estimates are country-specific; that is to say, each country’s data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

*Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around immunization coverage: a computational logic approach.

OFFICIAL coverage may differ across countries.

OFFICIAL coverage is different from published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where the available empirical data accurately reflect immunization system performance and those where the data are likely to be compromised and present a misleading view of immunization coverage while jointly estimating the most likely coverage levels for each country.

WHO and UNICEF estimates are country-specific; that is to say, each country’s data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

*Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around immunization coverage: a computational logic approach.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 12-23 months or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on the period of data collection.

DATA SOURCES.

ADMINISTRATIVE coverage: Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 12-23 months or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on the period of data collection.

ABBREVIATIONS

BCG: percentage of births who received one dose of Bacillus Calmette Guerin vaccine.

DTP1 / DTP3: percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.

Pol3: percentage of surviving infants who received the 3rd dose of polio containing vaccine. May be either oral or inactivated polio vaccine.

IPV1: percentage of surviving infants who received at least one dose of inactivated polio vaccine. In countries utilizing an immunization schedule recommending either (i) a primary series of three doses of oral polio vaccine (OPV) plus at least one dose of IPV where OPV is included in routine immunization and/or campaign or (ii) a sequential schedule of IPV followed by OPV, WHO and UNICEF estimates for IPV1 reflect coverage with at least one routine dose of IPV among infants <1 year of age among countries. For countries utilizing IPV containing vaccine use only, i.e., no recommended dose of OPV, the WHO and UNICEF estimate for IPV1 corresponds to coverage for the 1st dose of IPV.

Production of IPV coverage estimates, which begins in 2015, results in no change of the estimated coverage levels for the 3rd dose of polio (Pol3). For countries recommending routine immunization with a primary series of three doses of IPV alone, WHO and UNICEF estimated Pol3 coverage is based on that for the 3rd dose of polio vaccine regardless of vaccine type.

MCV1: percentage of surviving infants who received the 1st dose of measles containing vaccine in countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

MCV2: percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

RCV1: percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration nor are the data represented in the accompanying graph and data table.

HepBB: percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HepB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

HepB3: percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

Hib3: percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.

RotaC: percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.

PeV3: percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine.

PFV: percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children’s Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children’s Fund be liable for damages arising from its use.
The WHO and UNICEF estimates of national immunization coverage (vaccine) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Papua New Guinea - BCG

<table>
<thead>
<tr>
<th>Year</th>
<th>Estimate</th>
<th>Official</th>
<th>Administrative</th>
<th>Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>89</td>
<td>80</td>
<td>73</td>
<td>NA</td>
</tr>
<tr>
<td>2020</td>
<td>91</td>
<td>83</td>
<td>80</td>
<td>NA</td>
</tr>
<tr>
<td>2019</td>
<td>92</td>
<td>84</td>
<td>80</td>
<td>NA</td>
</tr>
<tr>
<td>2018</td>
<td>67</td>
<td>86</td>
<td>86</td>
<td>NA</td>
</tr>
<tr>
<td>2017</td>
<td>72</td>
<td>65</td>
<td>77</td>
<td>69</td>
</tr>
<tr>
<td>2016</td>
<td>62</td>
<td>77</td>
<td>61</td>
<td>NA</td>
</tr>
<tr>
<td>2015</td>
<td>52</td>
<td>68</td>
<td>68</td>
<td>NA</td>
</tr>
<tr>
<td>2014</td>
<td>52</td>
<td>57</td>
<td>57</td>
<td>NA</td>
</tr>
<tr>
<td>2013</td>
<td>45</td>
<td>47</td>
<td>47</td>
<td>NA</td>
</tr>
<tr>
<td>2012</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>NA</td>
</tr>
<tr>
<td>2011</td>
<td>52</td>
<td>45</td>
<td>45</td>
<td>NA</td>
</tr>
<tr>
<td>2010</td>
<td>42</td>
<td>45</td>
<td>45</td>
<td>NA</td>
</tr>
</tbody>
</table>

### Description:

2021: Estimate based on coverage reported by national government. Estimate challenged by: D-

2020: Estimate based on coverage reported by national government. Estimate challenged by: D-

2019: Estimate based on interpolation between data reported by national government. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. GoC=Assigned by working group. Consistency with other antigens.

2018: Estimate based on coverage reported by national government. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Estimate based on coverage reported by national government. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 69 percent based on 1 survey(s). Reported data reflects three quarters of expected district-level reports. Programme reports 3.5 months stock out at national level. GoC=Assigned by working group. See comment in 2018.


2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two month stock-out at national level. GoC=Assigned by working group. See comment in 2018.


2011: Reported data calibrated to 2005 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- ••• Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- •• Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- • There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-
2020: Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate challenged by: D-R-
2019: Based on previous year estimate. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
2018: Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
2017: Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 64 percent based on 1 survey(s). Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
2012: Reported data calibrated to 2005 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.
The WHO and UNICEF estimates of national immunization coverage (vaccine) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate is supported by reported data** [R+], **coverage recalculated with an independent denominator** from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- **Estimate is supported by at least one data source**; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- **2021**: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-
- **2020**: Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate challenged by: D-R-
- **2019**: Based on previous year estimate. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- **2018**: Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- **2017**: Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- **2016**: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- **2014**: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- **2013**: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- **2011**: Reported data calibrated to 2005 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data \([R^+]\), coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division \((D^+)\), and at least one supporting survey within 2 years \([S^+]\). While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; \([R^+]\), \([S^+]\), or \([D^+]\); and no data source, \([R^-]\), \([D^-]\), or \([S^-]\), challenges the estimate.
- There are no directly supporting data; or data from at least one source; \([R^-]\), \([D^-]\), \([S^-]\); challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

- **2021**: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-
- **2020**: Estimate informed by relative change in doses administered from 2018 levels to 2020. Programme reports half month vaccine stockout at national and district level. Estimate challenged by: D-R-
- **2019**: Based on previous year estimate. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- **2018**: Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- **2017**: Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- **2016**: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 48 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 48 percent based on 1st dose card or history coverage of 69 percent, 1st dose card only coverage of 52 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- **2014**: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two month stock-out at national level. GoC=Assigned by working group. See comment in 2018.
- **2013**: Reported data calibrated to 2005 and 2016 levels. Programme reports three months stock-out at national level. GoC=Assigned by working group. See comment in 2018.
- **2012**: Reported data calibrated to 2005 and 2016 levels. Rise in coverage is attributable to recovery from vaccine shortage. GoC=Assigned by working group. See comment in 2018.
- **2011**: Reported data calibrated to 2005 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.
Papua New Guinea - IPV1

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.

Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.

There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative’s Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-

2020: Based on estimate for DTP3 coverage for consistency but it may underestimate IPV1 coverage given that more IPV than DTP3 doses reported. Estimate challenged by: D-R-

2019: Based on estimate for DTP3 coverage. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Actual IPV1 coverage is likely lower than that estimated based on reported doses administered vis-a-vis the third dose of DTP. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.

2018: Estimate based on coverage reported by national government. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. Estimate based on reported data during period of introduction. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Estimate based on coverage reported by national government. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Estimate based on reported data during period of introduction. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: Estimate based on coverage reported by national government. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored during period of introduction. Reported data reflects three quarters of expected district-level reports. Inactivated polio vaccine in 2015, reporting starts in 2016. Unclear whether doses given as part of an intensification of routine vaccination are included in the reported coverage. Programme reports two months stock out of IPV at national level. GoC=Assigned by working group. See comment in 2018.

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.

Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.

There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-]; challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2021: 
Estimate reflects decline in reported coverage from 2020. Estimate challenged by: R-

2020: 
Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate challenged by: R-

2019: 
Based on previous year estimate. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: R-

2018: 
Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: 
Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: 
Estimate of 46 percent assigned by working group. Estimate is based on estimated DTP3 level. Reported administrative data suggests MCV1 coverage is lower than that for DTP3. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results may included doses delivered through campaign. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.

2015: 
Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

2014: 
Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two month stock-out at national level. GoC=Assigned by working group. See comment in 2018.

2013: 
Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

2012: 
Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

2011: 
Reported data calibrated to 2005 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.

2010: 
Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

2021: Estimate based on coverage reported by national government. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.

2020: Estimate based on coverage reported by national government. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.

2019: Estimate based on coverage reported by national government. Estimate is based on reported data on an exceptional basis relative to other antigens. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+] and at least one supporting survey within 2 years [S+] and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.

- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-]; challenges the estimate.

- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

For this revision, coverage estimates for the first dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine. Nationally reported coverage of rubella containing vaccine is not taken into consideration nor are they represented in the accompanying graph and data table.

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: R-

2020: Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate of 47 percent changed from previous revision value of 37 percent. Estimate challenged by: R-

2019: Based on previous year estimate. Estimate challenged by: R-

2018: Estimate based on estimated MCV1. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Estimate based on estimated MCV1. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

### Description:

**2021:** Estimate based on coverage reported by national government. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.

**2020:** Estimate based on coverage reported by national government. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.

**2019:** Estimate based on interpolation between reported values. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. GoC=Assigned by working group. Consistency with other antigens.

**2018:** Estimate based on coverage reported by national government. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

**2017:** Estimate based on coverage reported by national government. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

**2016:** Estimate based on coverage reported by national government. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored due to insufficient information regarding whether HepB doses were received within 24 hours of birth. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.

**2015:** Estimate based on coverage reported by national government. GoC=Assigned by working group. See comment in 2018.

**2014:** Estimate based on coverage reported by national government. Target population increase of 15 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.

**2013:** Estimate based on coverage reported by national government. Programme reports two months stock out at national level. GoC=Assigned by working group. See comment in 2018.

**2012:** Estimate based on coverage reported by national government. goC=Assigned by working group. See comment in 2018.

**2011:** Estimate based on coverage reported by national government. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.

**2010:** Estimate based on reported administrative estimate. Public - private sector discrepancy noted by WHO and UNICEF, however, adjustment inconsistently applied across antigens. GoC=Assigned by working group. See comment in 2018.

---

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimate</td>
<td>31</td>
<td>31</td>
<td>35</td>
<td>37</td>
<td>31</td>
<td>32</td>
<td>35</td>
<td>33</td>
<td>25</td>
<td>25</td>
<td>24</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Estimate GoC</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Official</td>
<td>35</td>
<td>31</td>
<td>35</td>
<td>37</td>
<td>31</td>
<td>32</td>
<td>35</td>
<td>33</td>
<td>25</td>
<td>21</td>
<td>24</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Administrative</td>
<td>31</td>
<td>27</td>
<td>30</td>
<td>34</td>
<td>27</td>
<td>28</td>
<td>31</td>
<td>28</td>
<td>20</td>
<td>21</td>
<td>24</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Survey</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>58</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.**

- **Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.**

- **There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.**

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.
The WHO and UNICEF estimates of national immunization coverage are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Papua New Guinea - HepB3

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimate</strong></td>
<td>67</td>
<td>72</td>
<td>69</td>
<td>69</td>
<td>57</td>
<td>52</td>
<td>46</td>
<td>36</td>
<td>35</td>
<td>35</td>
<td>39</td>
<td>31</td>
</tr>
<tr>
<td><strong>GoC</strong></td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
<td>🟢</td>
</tr>
<tr>
<td><strong>Official</strong></td>
<td>89</td>
<td>61</td>
<td>63</td>
<td>68</td>
<td>62</td>
<td>64</td>
<td>61</td>
<td>51</td>
<td>50</td>
<td>40</td>
<td>45</td>
<td>37</td>
</tr>
<tr>
<td><strong>Administrative</strong></td>
<td>89</td>
<td>57</td>
<td>59</td>
<td>64</td>
<td>58</td>
<td>58</td>
<td>57</td>
<td>46</td>
<td>45</td>
<td>40</td>
<td>45</td>
<td>37</td>
</tr>
<tr>
<td><strong>Survey</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>42</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

The WHO and UNICEF estimates of national immunization coverage are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

**Description:**

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-

2020: Based on previous year estimate. Reported data excluded. Observed decline in coverage is not explained by seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2019: Based on previous year estimate. Reported data excluded. Observed decline in coverage is not explained by seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2018: Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.


2014: Reported data calibrated to 2011 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.


2011: Estimate of 72 percent assigned by working group. Estimate based on estimated DTP3 coverage. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.


2009: Based on previous year estimate. Reported data excluded. Observed decline in coverage is not explained by seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2008: Based on previous year estimate. Reported data excluded. Observed decline in coverage is not explained by seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2007: Based on previous year estimate. Reported data excluded. Observed decline in coverage is not explained by seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2006: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2006-2007 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+] , coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-]; challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-

2020: Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate challenged by: D-R-

2019: Based on previous year estimate. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-

2018: Reported data calibrated to 2016 levels. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Reported data calibrated to 2016 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.


2014: Reported data calibrated to 2010 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.

2013: Reported data calibrated to 2010 and 2016 levels. GoC=Assigned by working group. See comment in 2018.


2011: Reported data calibrated to 2010 and 2016 levels. Administrative coverage is adjusted for vaccinations provided in the private sector. Previous surveys have consistently indicated higher coverage than administrative coverage. GoC=Assigned by working group. See comment in 2018.

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

-•••- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.

-••- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.

-•- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.
The WHO and UNICEF estimates of national immunization coverage (wunic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.

Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.

There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2021: Estimate reflects decline in reported coverage from 2020. Estimate challenged by: D-R-

2020: Estimate informed by relative change in doses administered from 2018 levels to 2020. Estimate challenged by: D-R-

2019: Based on estimate for DTP3 for consistency. Reported data excluded. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: R- 

2018: Estimate of 35 percent assigned by working group. Estimate is based on estimated DTP3. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. Estimate based on reported data during period of introduction. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.

2017: Estimate of 36 percent assigned by working group. Estimate is based on estimated DTP3. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Estimate based on reported data during period of introduction. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

2016: Estimate is based on reported data. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored during period of introduction. Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 35 percent modified for recall bias to 39 percent based on 1st dose card or history coverage of 58 percent, 1st dose card only coverage of 46 percent and 3rd dose card only coverage of 31 percent. Reported data reflects three quarters of expected district-level reports. Estimate based on reported data during period of introduction. GoC=Assigned by working group. See comment in 2018.

## 2016 Papua New Guinea Demographic and Health Survey 2016-2018

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>C or H &lt;12 months</td>
<td>67.1</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>BCG</td>
<td>Card</td>
<td>52.9</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>BCG</td>
<td>Card or History</td>
<td>69.4</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>BCG</td>
<td>History</td>
<td>16.5</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>DTP1</td>
<td>C or H &lt;12 months</td>
<td>60.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card</td>
<td>50</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card or History</td>
<td>63.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>DTP1</td>
<td>History</td>
<td>13.9</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>DTP3</td>
<td>C or H &lt;12 months</td>
<td>35</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card</td>
<td>35.9</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card or History</td>
<td>41.7</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>DTP3</td>
<td>History</td>
<td>5.8</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>HepB1</td>
<td>C or H &lt;12 months</td>
<td>60.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card</td>
<td>50</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card or History</td>
<td>63.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepB1</td>
<td>History</td>
<td>13.9</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>HepB3</td>
<td>C or H &lt;12 months</td>
<td>35</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card</td>
<td>35.9</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card or History</td>
<td>41.7</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepB3</td>
<td>History</td>
<td>5.8</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>HepBB</td>
<td>C or H &lt;12 months</td>
<td>55.5</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepBB</td>
<td>Card</td>
<td>43.3</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>HepBB</td>
<td>Card or History</td>
<td>57.5</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>HepBB</td>
<td>History</td>
<td>14.2</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>Hib1</td>
<td>C or H &lt;12 months</td>
<td>60.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>Hib1</td>
<td>Card</td>
<td>50</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>Hib1</td>
<td>Card or History</td>
<td>63.9</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>Hib1</td>
<td>History</td>
<td>13.9</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>Hib3</td>
<td>C or H &lt;12 months</td>
<td>35</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>Hib3</td>
<td>Card</td>
<td>35.9</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>Hib3</td>
<td>Card or History</td>
<td>41.7</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>Hib3</td>
<td>History</td>
<td>5.8</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>IPV1</td>
<td>C or H &lt;12 months</td>
<td>33.4</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>IPV1</td>
<td>Card</td>
<td>26.4</td>
<td>12-23 m</td>
<td>1069</td>
<td>61</td>
</tr>
<tr>
<td>IPV1</td>
<td>Card or History</td>
<td>39.1</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
<tr>
<td>IPV1</td>
<td>History</td>
<td>12.7</td>
<td>12-23 m</td>
<td>695</td>
<td>61</td>
</tr>
<tr>
<td>MCV1</td>
<td>C or H &lt;12 months</td>
<td>50.1</td>
<td>12-23 m</td>
<td>1763</td>
<td>61</td>
</tr>
</tbody>
</table>

## 2005 Papua New Guinea Demographic and Health Survey 2006

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>Card</td>
<td>66.7</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>BCG</td>
<td>Card or History</td>
<td>89.6</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card</td>
<td>66.5</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card or History</td>
<td>87.9</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card</td>
<td>53.7</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card or History</td>
<td>66.8</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card</td>
<td>64.8</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card or History</td>
<td>86.4</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card</td>
<td>53.3</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card or History</td>
<td>64.6</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>MCV1</td>
<td>Card</td>
<td>61.6</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>MCV1</td>
<td>Card or History</td>
<td>81.6</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
</tbody>
</table>
## Papua New Guinea - survey details

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pol1</td>
<td>Card</td>
<td>64.9</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>Pol1</td>
<td>Card or History</td>
<td>87.4</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>Pol3</td>
<td>Card</td>
<td>54.6</td>
<td>12-23 m</td>
<td>883</td>
<td>70</td>
</tr>
<tr>
<td>Pol3</td>
<td>Card or History</td>
<td>68.3</td>
<td>12-23 m</td>
<td>1254</td>
<td>70</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card or History</td>
<td>71</td>
<td>12-23 m</td>
<td>783</td>
<td>93</td>
</tr>
<tr>
<td>DTP3</td>
<td>History</td>
<td>4.2</td>
<td>12-23 m</td>
<td>783</td>
<td>93</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card</td>
<td>82.1</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card or History</td>
<td>88.1</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>HepB1</td>
<td>History</td>
<td>6</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card</td>
<td>68.7</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card or History</td>
<td>73.1</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>HepB3</td>
<td>History</td>
<td>4.4</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>Pol1</td>
<td>History</td>
<td>5.3</td>
<td>12-23 m</td>
<td>774</td>
<td>93</td>
</tr>
<tr>
<td>Pol3</td>
<td>Card</td>
<td>64</td>
<td>12-23 m</td>
<td>776</td>
<td>93</td>
</tr>
<tr>
<td>Pol3</td>
<td>Card or History</td>
<td>68.7</td>
<td>12-23 m</td>
<td>776</td>
<td>93</td>
</tr>
<tr>
<td>Pol3</td>
<td>History</td>
<td>4.7</td>
<td>12-23 m</td>
<td>776</td>
<td>93</td>
</tr>
</tbody>
</table>


Further information and estimates for previous years are available at:
https://data.unicef.org/topic/child-health/immunization/
https://immunizationdata.who.int/listing.html